Navigation Links
ISTA Pharmaceuticals Announces 2011 Guidance and Pipeline Update Webcast/Conference Call on January 5, 2011
Date:12/22/2010

IRVINE, Calif., Dec. 22, 2010 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will conduct a 2011 guidance and pipeline update webcast/conference call after the market closes on January 5, 2011.

President and Chief Executive Officer, Vicente Anido, Jr., Ph.D., and Chief Financial Officer and Vice President of Corporate Development, Lauren Silvernail, will provide 2011 guidance, give a commercial and new product pipeline update, and highlight key milestones for 2011.  The webcast/call will include a slide presentation; participants will be able to view the accompanying slides through ISTA's website.  After the call, the slides will be available for download at http://www.istavision.com/investors.html under "Presentations".Date: Wednesday, January 5, 2011Time: 4:30 p.m. Eastern TimeWebcast and Conference Call Access:Internet: http://www.istavision.com/investors.html Domestic dial-in: 800-299-9086International dial-in: 617-786-2903Passcode: 69989701The webcast/conference call will be webcast live and archived on ISTA's website until February 2, 2011.

To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888.  The access code for the replay is 57525060.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals, Inc., is the fourth largest and fastest growing branded prescription eye care business in the United States, with an expanding focus on allergy therapeutics.  ISTA currently markets five products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis.  The Company's development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain and nasal allergies.  Headquartered in Irvine, California, the Company generated 2009 revenues of $111 million.  For additional information about ISTA Pharmaceuticals, please visit the corporate website at www.istavision.com.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate
2. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
3. MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial
4. Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
5. Lotus Pharmaceuticals Announces Change of Directors
6. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
7. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
8. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
9. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. John A. MacPhee Resigns From Strativa Pharmaceuticals
11. Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)...   TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...
(Date:12/8/2016)...  A new study by a pair of Geisinger ... therapy to treat chronic pain is not only ineffective, ... consequences, including death. Palliative care physicians ... , M.D., authored the study which provides a review ... study was published in the December 2016 edition of ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
Breaking Medicine News(10 mins):